mvasi.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Sitemap: | ||
Meta Tags
| Title | Avastin® (bevacizumab) Biosimilar | MVASI® |
| Description | Find out more about MVASI® (bevacizumab-awwb) an Avastin® (bevacizumab) Biosimilar. See Important Safety & Prescribing |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 52.43.121.28 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
mvasi.com Valuation
|
US$13,016,774
Last updated: 2023-05-07 08:06:54
mvasi.com has Semrush global rank of 813,128. mvasi.com has an estimated worth of US$ 13,016,774, based on its estimated Ads revenue. mvasi.com receives approximately 1,501,936 unique visitors each day. Its web server is located in United States, with IP address 52.43.121.28. According to SiteAdvisor, mvasi.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$13,016,774 |
| Daily Ads Revenue | US$12,016 |
| Monthly Ads Revenue | US$360,465 |
| Yearly Ads Revenue | US$4,325,574 |
| Daily Unique Visitors | 100,130 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| mvasi.com. | A | 299 | IP: 52.43.121.28 |
| mvasi.com. | A | 299 | IP: 52.25.187.138 |
| mvasi.com. | NS | 86400 | NS Record: ns-699.awsdns-23.net. |
| mvasi.com. | NS | 86400 | NS Record: ns-1341.awsdns-39.org. |
| mvasi.com. | NS | 86400 | NS Record: ns-1956.awsdns-52.co.uk. |
| mvasi.com. | NS | 86400 | NS Record: ns-469.awsdns-58.com. |
HtmlToTextCheckTime:2023-05-07 08:06:54
| MVASI® Indications MVASI® is a vascular endothelial growth factor inhibitor indicated for the treatment of: MVASI®, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer (mCRC). ... Read More MVASI®, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use : MVASI® is not indicated for adjuvant treatment of colon cancer. MVASI®, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC). MVASI® is indicated for the treatment of recurrent glioblastoma (GBM) in adults. MVASI®, in combination with interferon-alfa, is indicated for |
HTTP Headers
HTTP/1.1 403 Forbidden Server: awselb/2.0 Date: Wed, 27 Oct 2021 15:57:24 GMT Content-Type: text/html Content-Length: 118 Connection: keep-alive |
mvasi.com Whois Information
Domain Name: MVASI.COM Registry Domain ID: 1548956829_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2021-02-20T10:13:10Z Creation Date: 2009-03-24T02:27:15Z Registry Expiry Date: 2023-03-24T02:27:15Z Registrar: MarkMonitor Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2083895740 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS-1341.AWSDNS-39.ORG Name Server: NS-1956.AWSDNS-52.CO.UK Name Server: NS-469.AWSDNS-58.COM Name Server: NS-699.AWSDNS-23.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-15T12:15:46Z <<< |